Yu Dechao (Chinese: 俞德超, born February 4, 1964), also known as Michael Yu,[1] is the founder and CEO of the Chinese pharmaceutical company Innovent Biologics.[2] He received a PhD degree in Genetics from the Chinese Academy of Sciences[3] and completed post-doctoral training in pharmaceutical chemistry at the UCSF.[4] As an inventor and owner of more than 60 patents (including 38 U.S. patents),[4] Yu established Innovent Biologics in 2011.[5] He is a professor and doctoral supervisor of Sichuan University, a visiting professor of Zhejiang University and an adjunct professor at Suzhou University,[6] the chairman of the board of the Chinese Antibody Society.[7]
Biography
editYu was the vice president of Research and Development at Applied Genetic Technologies Corporation (Nasdaq: AGTC) and Calydon, Inc.,[8] the latter was acquired by Cell Genesys, Inc. in 2001, where he worked for three years following the acquisition.[9] In 2011, Yu founded Innovent Biologics, and it became listed on the Main Board of the HKEX with the stock code: 01801.HK. on October 31, 2018.
Achievements in biomedicine
editYu invented and developed three "Class I" drugs in China.[10] He invented Oncorine (an oncology product),[11] which is the world's first oncolytic virus product;[12] Tyvyt (generic name: sintilimab), which is the domestically developed PD-1 antibody jointly developed by Innovent Biologics and Eli Lilly and Company,[13] and the key clinical results of Tyvyt in patients with r/r cHL have been published by the Lancet Haematology.[14] And Tyvyt has been officially approved by the National Medical Products Administration[15] for marketing in China for relapsed or refractory classical Hodgkin's lymphoma (r/r cHL) as the first approved indication.[16]
Awards and recognition
editYu Dechao was selected as "Most Influential Overseas Returnee in Life Sciences" in 2013; one of the "Top Ten Figure of Innovation in China" in 2014; "E&Y Entrepreneur of the Year in China" in 2015; "Distinguished Entrepreneur of Jiangsu Province" in 2016;[7] national "Person of the Year in Innovation for Science and Technology in 2016" in January 2017;[7] awarded as "The Seventh National Overseas Returnee Contributions Awards" in 2018.[9]
References
edit- ^ Macular Degeneration: New Insights for the Healthcare Professional: 2013 Edition: ScholarlyBrief. ScholarlyEditions. 22 July 2013. pp. 22–. ISBN 978-1-4816-5391-6.
- ^ "Capital Group Eyes Pre-IPO Stake in China Biotech Unicorn". Bloomberg News. Retrieved 15 January 2018.
- ^ "Michael Yu:High Quality Drugs Should be Affordable to Ordinary People". Chinese Academy of Sciences. Retrieved 1 December 2015.
- ^ a b "Recruitment program a magnet for talent". China Daily. Apr 20, 2017.
- ^ "Capital Group eyeing stake in China biotech unicorn". The Star (Malaysia). Retrieved 17 January 2018.
- ^ "关于公布江苏省第五批产业教授（兼职）" (PDF). Southeast University. Retrieved Dec 28, 2017.
- ^ a b c "集贤大讲坛：开发出中国老百姓用得起的高质量生物药". Zhejiang A & F University. Retrieved Apr 13, 2017.
- ^ Pablo Hernáiz Driever; Samuel D. Rabkin (1 January 2001). Replication-competent Viruses for Cancer Therapy. Karger Medical and Scientific Publishers. pp. 56–. ISBN 978-3-8055-7248-4.
- ^ a b "directors and senior management" (PDF). etnet.com. Retrieved 18 October 2018.
- ^ "加快迈向新药研发大国". People's Daily. Retrieved Feb 20, 2019.
- ^ Shuren Zhang (30 May 2016). Progress in Cancer Immunotherapy. Springer. pp. 244–. ISBN 978-94-017-7555-7.
- ^ Liang, M. (2018). "Oncorine, the World First Oncolytic Virus Medicine and its Update in China". Current Cancer Drug Targets. 18 (2): 171–176. doi:10.2174/1568009618666171129221503. PMID 29189159.
- ^ "China Approves Tyvyt For Hodgkin's Lymphoma". Asian Scientist Magazine. Apr 20, 2017. Retrieved January 9, 2019.
- ^ Ansell, S. M. (2019). "Sintilimab: Another effective immune checkpoint inhibitor in classical Hodgkin lymphoma". The Lancet. Haematology. 6 (1): e2–e3. doi:10.1016/S2352-3026(18)30210-2. PMID 30612711. S2CID 58561198.
- ^ "治疗霍奇金淋巴瘤的PD-1抗体药物信迪利单抗注射液获批上市". nmpa.gov.cn. Retrieved 28 December 2018.
- ^ Hoy, S. M. (2019). "Sintilimab: First Global Approval". Drugs. 79 (3): 341–346. doi:10.1007/s40265-019-1066-z. PMID 30742278. S2CID 59945274.